Jim Woods

Analyst Articles

If you just looked at the latest headlines for specialty drugmaker Vertex Pharmaceuticals (NASDAQ: VRTX), you might find yourself a bit confused. On the surface, the company actually showed a profit in the fourth quarter, with net income of $44.3 million, or $0.19 per share. That’s a huge improvement over… Read More

When a high-profile activist investor issues a statement with some aggressive suggestions about how a company can improve its business, usually one of two things happen. Either the company’s stock gets a huge boost on the possibilities, or the Street reads the comments as an epic fail and the shares… Read More

When a high-profile activist investor issues a statement with some aggressive suggestions about how a company can improve its business, usually one of two things happen. Either the company’s stock gets a huge boost on the possibilities, or the Street reads the comments as an epic fail and the shares… Read More

Big retail can be a tough business. Sometimes your product mix appeals to shoppers; sometimes you get strong holiday traffic, and sometimes management makes all the right restructuring moves designed to cut costs and maximize earnings. For bellwether retailer Macy’s (NYSE:M), that sometime is right now. After a series of… Read More